^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Excerpt:
...Documented presence of RAS-RAF-MEK pathway mutations including BRAF, KRAS and NRAS....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

Published date:
05/30/2017
Excerpt:
Of the gynaecological cancers, 3/5 patients (60%) achieved a partial response (KRAS-mutant endometrial and ovarian cancer and BRAF-mutant ovarian). RO5126766 has shown exciting preliminary activity across a wide range of RAS- and RAF-mutated malignancies, with significant response rates in lung and gynaecological cancers.
DOI:
10.1200/JCO.2017.35.15_suppl.2506
Trial ID: